NetNoggin is a company that specializes in pharmaceutical marketing. The new offering, called NetNog: #genesis Cystic Fibrosis Patient and Caregiver Journeys, is part of the company’s NetNog: #genesis Cystic Fibrosis pharmaceutical marketing report introduced in October 2018. The new launch is in honor of Rare Disease Day today (Feb. 28).
The NetNog CF Patient and Caregiver Journeys report offers pharmaceutical companies five perspectives about what the CF journey means to patients and caregivers. This provides a head-start to companies in their commercialization strategy and development of products that can better help the CF community.
The five CF journey perspectives include:
- Clinical patient pathway — the patient’s journey from symptom onset to end-of-life;
- Patient experiences and life lessons beyond the clinical setting;
- Patient emotional journey according to emotions expressed by patients;
- Caregiver journey based on caregivers’ descriptions about how CF affects their loved ones;
- Caregiver emotional journey based on caregivers’ emotions as they help their loved ones and grow in their roles.
“Growing up, I had a neighbor who passed away from cystic fibrosis, which had a profound effect on me. During college, I volunteered to assist parents by performing chest physical therapy on children with cystic fibrosis,” Diana Conger, CEO at NetNoggin, said in a press release.
The Cystic Fibrosis News Today forums are a place to connect with other patients, share tips and talk about the latest research. Join today!
“With this in mind and advances in research, we chose cystic fibrosis as our first NetNog: #genesis report and first syndicated patient/caregiver journeys report,” Conger said.
NetNog: #genesis market research was introduced to provide pharmaceutical companies in-depth information about disease-specific data. This market research tool can guide companies in developing relevant and targeted products to improve patients’ and caregivers’ quality of life.
The report highlights the real-world unmet needs of the CF community, and identifies gaps in research, treatment, and care.